Positive results of PARP inhibitor and CAR T-cell treatments highlight advances in research for neuroblastoma.

Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer ...

Mohammad Mahmoud, MD, MS, reviews important updates in metastatic prostate cancer presented at AUA 2025, including promising ...

The U.S. Food and Drug Administration (FDA) on Monday cleared Lantern Pharma Inc.’s (NASDAQ:LTRN) Investigational New Drug Application (IND) for a Phase 1b/2 trial for LP-184 in triple-negative breast ...

Mesothelioma is an aggressive cancer that forms in the lining of the lungs or abdomen and is linked to breathing in or ...

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

It was during a dream solo three-month trip to the Bahamas in July 2022 that Louisa Lloyd realised something was seriously ...

Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies ...

Pancreatic cancer remains one of the most formidable oncological challenges of our time. Known for its late detection and ...

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

AstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in 2014 to treat ovarian cancer. The drug has gone on to become a huge success ...